Han Kim

Company: Bolt Biotherapeutics

Job title: Senior Director

Seminars:

Future Directions in Claudin-Targeted Therapy Development 3:15 pm

Implementing emerging trends and innovations in Claudin-targeted therapies, including next-generation antibody technologies and novel therapeutic modalities Understanding the potential of targeting other claudin isoforms, such as Claudin 6, in different cancer types and the associated scientific challenges and opportunities Reviewing advancements in preclinical models and technologies that support the development of more effective and safer…Read more

day: Conference Day 2